Zacks Small Cap Comments on ABEO Q3 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Analysts at Zacks Small Cap issued their Q3 2025 earnings estimates for shares of Abeona Therapeutics in a research note issued on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings per share of ($0.34) for the quarter. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics' Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at $0.40 EPS.

A number of other equities research analysts have also recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, March 24th. Oppenheimer began coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price on the stock. Finally, StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, March 24th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, Abeona Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $17.50.

Abeona Therapeutics Price Performance

Shares of ABEO stock traded down $0.19 during trading hours on Thursday, hitting $4.79. The company's stock had a trading volume of 413,236 shares, compared to its average volume of 408,378. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $8.45. The stock has a market cap of $232.24 million, a price-to-earnings ratio of -1.78 and a beta of 1.79. The business has a fifty day moving average of $5.42 and a 200-day moving average of $5.81.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the third quarter valued at approximately $84,000. JPMorgan Chase & Co. increased its holdings in shares of Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock worth $424,000 after buying an additional 28,606 shares during the last quarter. Western Standard LLC raised its position in shares of Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company's stock worth $10,732,000 after buying an additional 110,998 shares during the period. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics in the third quarter valued at $151,000. Finally, XTX Topco Ltd purchased a new stake in Abeona Therapeutics during the third quarter valued at about $160,000. Institutional investors and hedge funds own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.